GI CONNECT has summarised the highlights of the recent ASCO GI 2018 meeting for you.
Cancers of the liver, small intestine and pancreas tract by Dr. Efrat Dotan, Fox Chase Cancer Center, USA
GI CONNECT has summarised the highlights of the recent ASCO GI 2018 meeting for you.
Cancers of the liver, small intestine and pancreas tract by Dr. Efrat Dotan, Fox Chase Cancer Center, USA
Ass. Prof. Efrat Dotan is an Assistant Professor of Medical Oncology at Fox Chase Cancer Center, in Philadelphia. She graduated from the Technion Institute of Technology Medical School in Israel and moved to the US to pursue her specialized training. She completed her residency at Lenox Hill Hospital in New York, and her hematology/oncology fellowship at Fox Chase Cancer Center. Ass. Prof. Dotan specializes in the management of patients with gastrointestinal malignancies, specifically pancreatic cancer. Her research interest is in development of new treatment options for patients with gastrointestinal cancers. She is the PI for multiple clinical trials in this arena. Ass. Prof. Dotan is a member of the Gastrointestinal Malignancies Committee of the Eastern Cooperative Oncology Group (ECOG) and serves as the PI for multiple studies. She also serves as a member of the Pancreatic Cancer Guideline Panel for the National Comprehensive Cancer Network (NCCN). Dr Dotan’s other interest is in the management of older patients with cancer, and tools to improve the care of this patient population. She has led multiple research projects evaluating the care of older patients with gastrointestinal malignancies. She is a senior member of the Cancer and Aging Research Group, and the chair of the Older Adult Oncology Guidelines for NCCN.
Research grants/clinical trials paid to the institution: Eli Lilly, Gilead, Lutris, Zymworks, Relay, Ipsen, AstraZeneca, MedImmune, Incyte
Honorarium: Pfizer, Incyte, Helsinn, Taiho, G1 Therapeutics
10 years of independent medical education in GI oncology
Journey through a patient case from testing and diagnosis to treatment and AE management
Looking beyond the obvious mutations in non-small-cell lung cancer
Medical experts discuss current and upcoming treatment strategies to use after CDK4/6 inhibitors in patients with ER+/HER2- advanced breast cancer
Maximising outcomes for patients with advanced CRC
Make decisions for your patient at two key stages in their journey